Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Ahead of its Analyst Day event on Thursday, Moderna (MRNA) indicated ~10% revenue growth for next year and increased its ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

Moderna says it is in the process of developing a single-shot vaccine that could serve as a COVID-19 booster shot and a flu shot. In a press release Thursday touting its fifth annual "R&D Day," ...

Three out of four adults in the United States live with conditions that can increase the risk of severe illness. 9 Chronic ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...